Compare · CORT vs MRK
CORT vs MRK
Side-by-side comparison of Corcept Therapeutics Incorporated (CORT) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CORT and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $298.33B, about 38.3x CORT ($7.80B).
- Over the past year, CORT is up 4.5% and MRK is up 53.1% - MRK leads by 48.6 points.
- MRK has been more active in the news (29 items in the past 4 weeks vs 24 for CORT).
- MRK has more recent analyst coverage (25 ratings vs 15 for CORT).
- Company
- Corcept Therapeutics Incorporated
- Merck & Company Inc.
- Price
- $72.77-2.84%
- $120.88+0.51%
- Market cap
- $7.80B
- $298.33B
- 1M return
- +39.53%
- +6.46%
- 1Y return
- +4.53%
- +53.15%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 24
- 29
- Recent ratings
- 15
- 25
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest CORT
- Chief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65 and sold $1,412,000 worth of shares (20,000 units at $70.60) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Lyon Joseph Douglas was granted 1,074 shares and covered exercise/tax liability with 269 shares, increasing direct ownership by 13% to 7,035 units (SEC Form 4) (tax liability)
- Chief Development Officer Guyer William was granted 1,754 shares, increasing direct ownership by 79% to 3,985 units (SEC Form 4)
- Officer Maduck Sean exercised 25,000 shares at a strike of $8.27, sold $1,755,183 worth of shares (25,000 units at $70.21) as part of a pre-agreed trading plan, was granted 1,230 shares and covered exercise/tax liability with 452 shares, increasing direct ownership by 9% to 9,755 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Mokari Atabak exercised 40,000 shares at a strike of $19.26, sold $2,800,004 worth of shares (40,000 units at $70.00) as part of a pre-agreed trading plan, was granted 1,268 shares and covered exercise/tax liability with 395 shares, increasing direct ownership by 6% to 16,130 units (SEC Form 4) (tax withholding)
- Chief Business Officer Robb Gary Charles was granted 1,552 shares and covered exercise/tax liability with 358 shares, increasing direct ownership by 5% to 25,681 units (SEC Form 4) to satisfy tax liability
- SEC Form 8-K filed by Corcept Therapeutics Incorporated
- Chief Executive Officer Belanoff Joseph K gifted 300,000 shares, received a gift of 300,000 shares and sold $895,252 worth of shares (12,837 units at $69.74) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Lyon Joseph Douglas sold $325,000 worth of shares (5,000 units at $65.00), decreasing direct ownership by 45% to 6,230 units (SEC Form 4)
- Officer Maduck Sean exercised 75,000 shares at a strike of $8.27 and sold $4,918,944 worth of shares (75,000 units at $65.59) as part of a pre-agreed trading plan (SEC Form 4)
Latest MRK
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen
- SEC Form 4 filed by Director Lavizzo-Mourey Risa J